Cell cycle analysis using flow cytometry (FC) to measure cellular DNA content is a common procedure in drug mechanism of action studies. Although this technique lends itself readily to cell lines that grow in suspension, adherent cell cultures must be resuspended in a cumbersome and potentially invasive procedure that normally involves trypsinization and mechanical agitation of monolayer cultures. High-content analysis (HCA), an automated microscopy-based technology, is well suited to analysis of monolayer cell cultures but provides intrinsically less accurate determination of cellular DNA content than does FC and thus is not the method of choice for cell cycle analysis. Using Cellomics's ArrayScan TM reader, the authors have developed a 4-color multiparametric HCA approach for cell cycle analysis of adherent cells based on detection of DNA content (4,6-diamidino-2-phenylindole [DAPI] fluorescence), together with the known cell cycle markers bromo-2-deoxyuridine (BrdU) incorporation, cyclin B1 expression, and histone H3 (Ser28) phosphorylation within a single cell population. Considering all 4 markers together, a reliable and accurate quantification of cell cycle phases was possible, as compared with flow cytometric analysis. Using this assay, specific cell cycle blocks induced by treatment with thymidine, paclitaxel, or nocodazole as test drugs were easily monitored in adherent cultures of U-2 OS osteosarcoma cells. (Journal of Biomolecular
INTRODUCTION
O NE OF THE MOST CURRENTLY PURSUED STRATEGIES in oncology drug discovery is the development of therapeutic compounds able to block cell proliferation and eventually induce apoptosis through specific inhibition of cell cycle machinery. 1 Accurate, medium-throughput assays for the multiparametric quantification of cell cycle phases thus represent highly desirable tools for the characterization of the cellular mechanism of action of pharmacologically active compounds and for the screening of chemical libraries. 2, 3 To date, a wealth of data supports the use of flow cytometry (FC) as the technique of choice for multiparametric analysis of the cell cycle. 4 For example, FC approaches have been described for 3-parameter bromo-2-deoxyuridine (BrdU)/cyclin B1/DNA analysis 5 or phospho-histone H3/cyclin A/cyclin B1 analysis. 6 A strength of cytometry methods is that they commonly enable simultaneous monitoring of multiple cellular markers. Such methods are, however, limited to the analysis of cell suspensions and consequently fail to adequately capture data relating to the morphology of adherent cells. In general, they do not allow investigation of the subcellular localization of labeled markers, and quantitation of total cell populations is difficult using FC analysis.
During the past years, novel techniques based on microscopybased imaging have emerged for multiparametric analysis of cell cycle phases. For example, laser scanning cytometry (LSC) has been employed for biparametric analysis of cyclin B1 expression and DNA content in primary human malignancies. 7 Several strategies have been pursued to increase the number of different-color channels to be acquired by imaging microscopy. For example, a luminescence imaging microscopy approach was described to detect 5 photoluminescent dyes in a single specimen, based on the separation of photoluminescent signals by their differences in spectra and decay times using timeresolved detection. 8 Another approach took advantage of the serial removal of the fluorescence stain using a combination of denaturation and elution techniques to successfully detect the concentration of at least 6 different antigens in each cell. 9 High-content analysis (HCA) is a novel imaging approach that uses fluorescent probes and automated microscopy to quantify multiple cellular markers at the single-cell level, with the ArrayScan TM system (Cellomics, Pittsburgh, PA) being one of the leading technology platforms in this field. The possibility to acquire and to quantify up to 4 fluorescence channels by means of the ArrayScan TM system was demonstrated by Minguez and coworkers, 10 who developed a staining procedure for the simultaneous analysis of DNA (Hoechst staining), α-tubulin, phosphohistone H3, and phospho-RSK90. Here we show a 4-color approach to simultaneously determine DNA content, BrdU incorporation, cyclin B1 expression, and histone H3 phosphorylation in a cell population within a single acquisition with the ArrayScan TM high-content analysis system.
Cyclin B1 is an established G2/M marker: it starts to appear in late S phase and accumulates in the cytoplasm during the G2 phase 11 (Fig. 1A) . In early mitosis (prophase), cyclin B1 translocates to the nucleus, and its expression level remains sustained until poly-ubiquitination-mediated degradation at the end of mitosis. Histone H3 plays a key role in mitotic chromosome condensation: 12 it is specifically phosphorylated during mitosis at Ser10 and Ser28 residues by the Aurora-B kinase, 13 supporting the use of phospho-histone H3 Ser28 as a specific mitotic marker.
Because BrdU replaces thymidine during DNA synthesis, BrdU pulse labeling for short periods (15-20 min) catches S phase cells actively engaged in DNA synthesis. 14, 15 Classical BrdU immunostaining procedures require that chromatin is previously denaturated to enable antibody binding to incorporated BrdU. 14 Usually, the denaturation step is performed by pretreating samples with HCl, but such harsh procedures can alter cell morphology and interfere with the simultaneous immunostaining of other cellular antigens. 16 We previously described a triple 4,6-diamidino-2-phenylindole (DAPI)/BrdU/ p-H3 staining approach for cell cycle analysis subsequent to HCl treatment, 17 in which our protocol ensured that chromatin denaturation did not significantly interfere with either DAPI or p-H3 fluorescence. However, by applying the same procedure to stain BrdU together with cytoplasmic antigens, such as cyclin B1, HCl treatment was indeed found to interfere with cytoplasmic staining (not shown). Because nuclease treatment, due to its milder nature, might represent an alternative approach to detect incorporated BrdU without adversely affecting cell morphology and integrity, 16, 18 we established a multiple staining procedure by coupling BrdU immunostaining following nuclease digestion to cyclin B1, phospho-H3 (Ser28), and DAPI staining.
By combining these 4 independent cell cycle markers, we were able to perform high-content cell cycle analysis of asynchronously growing cells and to follow specific cell cycle blocks induced by treatment with thymidine, paclitaxel, or nocodazole. In particular, high thymidine doses induce cell cycle arrest at the G1/S border, 19, 20 paclitaxel causes a late G2/M block via prevention of mitotic spindle assembly, 21, 22 and nocodazole completely blocks the self-assembly of tubulin, inducing a reversible M phase block. 23, 24 Cell cycle phase percentages calculated with this novel HCA approach were in accord with flow cytometric evaluation of DNA content and BrdU incorporation, used as a reference technique. We therefore propose this approach for the screening of cell cycle-specific inhibitors or for the study of the mechanism of action of novel antiproliferative compounds.
MATERIALS AND METHODS

Chemicals
Rabbit polyclonal anticyclin B1 antibody and goat antiphospho-histone H3 (Ser28) antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA); murine anti-BrdU antibody and nuclease reagent were obtained within the Cell Proliferation Fluorescence Kit (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK); Cy TM 2-conjugated donkey antigoat IgG antibody, Cy TM 3-conjugated donkey antirabbit IgG antibody, and Cy TM 5-conjugated donkey antimouse AffiniPure IgG antibodies were purchased from Jackson ImmunoResearch (West Grove, PA); and BrdU, DAPI, propidium iodide (PI), nocodazole, thymidine, and paclitaxel (Taxol ® ) were obtained from Sigma-Aldrich (St. Louis, MO).
Cell culture and treatments
The osteosarcoma cell line U-2 OS, obtained from American Type Culture Collection (ATCC, Manassas, VA), was grown in McCoy's medium (Gibco BRL, Gaithersburg, MD) containing 2 g/L glucose, supplemented with 15% (v/v) heat-inactivated fetal bovine serum (Gibco BRL), L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 mg/mL). For experiments performed in 96-well microplates, cells were seeded at a density of 8000/well in 96-well poly-L-lysine-coated clearbottomed plates (PerkinElmer Life Sciences, Boston, MA) 16 h before treatments. For cell cycle progression analysis, cells were treated with 0.17 µM nocodazole for 16 h, following which mitotic cells were detached by shaking, collected, and washed with growth medium in the presence of 10% (v/v) serum. Mitotic cells were replated in nocodazole-free medium at different time points before fixation. Then, 50 µM BrdU was added to the medium 15 to 20 min before fixation.
Flow cytometry
For flow cytometric analysis of DNA content, cells were detached with trypsin/EDTA solution and fixed in 70% (v/v) ethanol for 30 min. Fixed cells were washed with phosphatebuffered saline (PBS) and stained with a solution containing 25 µg/mL PI in PBS, 15 µg/mL RNase A (Sigma-Aldrich), and 0.125 µg/mL Nonidet P40 (Sigma-Aldrich) for 60 min in the dark. For each sample, at least 10,000 cells were analyzed using a FACScalibur system (Beckton Dickinson, Franklin Lakes, NJ). Cell cycle populations were quantified from DNA histograms with the ModFit LT v3.0 software package, purchased from Verity Software House (Topsham, ME).
For biparametric flow cytometry analysis of DNA content and BrdU incorporation, cells were fixed, washed with PBS/1% (w/v) bovine serum albumin (BSA), and resuspended in 3N HCl for 20 min, as previously described. 14 After washing with 0.1 M sodium tetraborate (pH 8.5) to stop acid denaturation, cells were incubated for 60 min at room temperature in the dark with 200 µL primary antibody solution containing 180 µL Tween-20 0.5% (v/v) in PBS, 1% (w/v) BSA, 1% (v/v) normal goat serum (NGS), and 20 µL anti-BrdU monoclonal antibody (clone B44), obtained from Beckton Dickinson. After washing with PBS, cells were incubated for 1 h with FITC-conjugated F(ab')2 fragment goat antimouse IgG (Jackson Immuno-Research), diluted 1:50 in 0.5% (v/v) Tween-20, 1% (w/v) BSA, and 1% (v/v) NGS in PBS for 1 h at room temperature in the dark. After incubation with secondary antibody, cells were washed with PBS, resuspended in 2 µg/mL PI in PBS plus RNase, and incubated overnight.
Fluorescence immunocytochemistry
For fluorescence-based high-content analysis, cells were fixed for 20 min by adding 100 µL formaldehyde 7.4% (v/v) solution to 100 µL medium, and then cells were washed with PBS and permeabilized with 0.3% (v/v) Triton X-100 (Sigma-Aldrich) in PBS for 15 min. For triple immunostaining (phospho-H3, cyclin B1, BrdU), cells were saturated with 1% (w/v) BSA for 1 h, and then anti-phospho-histone H3 (Ser28) and anticyclin B1 antibodies were added together at the recommended dilution (1:100) in PBS containing 1% (w/v) BSA and 0.3% (v/v) Tween-20 (Sigma-Aldrich) for 1 h at 37 °C. The solution was removed and cells were washed twice with PBS, and then anti-BrdU antibody diluted 1:100 in a nuclease solution (Cell Proliferation Fluorescence Kit, Amersham Biosciences) was added. Cells were washed twice with PBS, and antigoat Cy TM 2, antirabbit Cy TM 3, and antimouse Cy TM 5-conjugated secondary antibodies were added together at the recommended dilution (1:500) in PBS containing 1% (w/v) BSA, 0.3% (v/v) Tween-20, and 1 µg/mL DAPI for 1 h at 37 °C. After incubation, cells were washed twice with PBS, and 200 µL PBS was left in each well. All liquid handling was performed using a Biomek 2000 workstation (Beckman Coulter, Fullerton, CA).
Image acquisition and high-content analysis
The ArrayScan TM 4.0 High Content Screening reader (Cellomics), used to quantify cell cycle parameters by immunofluorescence staining, has been previously described. 17 A quadruple band fluorescence XF93 excitation filter (Omega Optical, Brattleboro, VT) was used to acquire images in the DAPI (365WB50), green (475RDF40), red (560DF15), and far-red (655DF30) channels with a 10× objective by exposing fields for fixed times. For each sample, at least 9 fields were automatically acquired and analyzed by the ArrayScan TM software.
Fluorescence intensity histograms and dot plots were obtained by scoring at least 800 cells with the Multiparameter Cytotoxicity 1 algorithm (Cellomics), which allows acquisition of fluorescence intensity in 2 nuclear channels and 1 cytoplasmatic channel within a single measurement. Histograms of fluorescence distribution were generated using an Excel macro developed by the authors; the entire fluorescence range (1-4095) of ArrayScan TM data was subdivided into 200 bins, and 2-dimensional dot plots were subsequently created using Excel software, whereas 3-dimensional dot plots were composed using Sigma Plot 8.0 for Windows (SPSS Ltd, Surrey, UK).
RESULTS AND DISCUSSION
Method development
Human U-2 OS osteosarcoma cells were seeded at a density of 8000 cells/well in 96-well plates and cultured overnight. Cells were exposed to 50 µM BrdU 15 to 20 min before fixation and then immunostained with murine anti-BrdU, rabbit anticyclin B1, and goat anti-phospho-histone H3 (Ser28) antibodies and counterstained with DAPI as described in Materials and Methods. As described above, BrdU incorporation, cyclin B1 expression, and histone H3 phosphorylation are events occurring in specific cell cycle phases ( Fig. 1A) . A nondestructive staining procedure for BrdU based on nuclease pretreatment 16 was applied to preserve cellular integrity and allow coimmunostaining of other cellular antigens. Moreover, primary and secondary antibodies were selected for minimal cross-reactivity.
The ArrayScan TM high-content screening reader (Cellomics) was used to acquire 4-color fluorescence signals. Figure 1B shows representative pictures of asynchronous U-2 OS cells obtained with the ArrayScan TM system in the blue (DAPI), green (phospho-H3), red (cyclin B1), and far-red (BrdU) fluorescence channels after the 4-color staining procedure. Cells in different cell cycle phases can be readily identified by their specific multiple staining pattern. Figure 1C reports examples of individual cells differentially stained depending on their specific cell cycle phase. Cells negative for BrdU/cyclin B1/p-H3 immunostaining are assigned as the G0/G1 phase. S phase cells can be identified by virtue of positive staining for BrdU incorporation, whereas S/G2 transition cells exhibit positive staining for both BrdU and cyclin B1. G2 phase cells can be identified by cytoplasmic cyclin B1 staining but no BrdU incorporation. At the entry into mitosis, starting from prophase, several events occur simultaneously: cyclin B1 translocates to the nucleus, histone H3 Ser28 is phosphorylated, and nuclear chromatin condenses. Both cyclin B1 and p-H3 staining completely disappear at cytokinesis, following which the newly derived daughter cells show a G0/G1 phase fluorescence staining pattern (Fig. 1C) .
Cells were thus identified by automated image analysis on the basis of their nuclear fluorescence by DAPI staining, following which fluorescence intensity distributions related to DAPI, nuclear BrdU, cytoplasmatic cyclin B1, and nuclear p-H3 were generated. Figure 2 shows fluorescence histograms related to these 4 cell cycle markers obtained from the same cell population. Because DAPI was added at saturating doses, it was assumed that the DAPI fluorescence intensity signal is proportional to DNA content, and thus a flow cytometry-like DNA distribution could be derived from measurement of nuclear total fluorescence in the DAPI channel, with a clear G1 peak centered at about 200,000 and a G2/M peak centered at about 400,000 (see also Fig. 4A for comparison). Visual inspection of derived histograms allowed application of arbitrary thresholds (dotted lines) to each cell cycle marker fluorescence distribution for designation of positively stained cells. From this analysis, 44.2% of cells resulted positive for BrdU incorporation, 33.4% for cyclin B1 expression, and 0.9% for p-H3 (Ser28) (Fig. 2) .
To demonstrate that the staining procedure and the image analysis algorithms used were devoid of cross-talking among the fluorescence channels, we reanalyzed the same sample population shown in Figure 2 by biparametric visualization of all the reciprocal fluorescence channel combinations. Figure 3A represents the DAPI fluorescence (proportional to DNA content) plotted against the BrdU signal. Note that the shape of the dot distribution obtained resembles a typical flow cytometry BrdU/DNA biparametric distribution of asynchronous growing cells (for comparison, see Moreover, BrdU fluorescence intensity was plotted against cyclin B1 fluorescence (Fig. 3D) , and BrdU fluorescence intensity was plotted against p-H3 fluorescence ( Fig. 3E) : in this case, a negligible fraction of the cells (0.1%) resulted double positive, confirming that none of the BrdU incorporation signal correlated with phospho-histone H3 staining, as might occur due to fluorescence cross-talking or other experimental artifacts. Finally, cyclin B1 fluorescence was plotted against phospho-H3 fluorescence ( Fig. 3F) : no cells were found single positive for phospho-histone H3, indicating that this staining is found exclusively within the cyclin B1 positive population, as expected. All values of positively stained cells obtained by the 4-color staining procedure were nearly identical to those obtained for each single stain (data not shown).
Multiparametric cell cycle analysis of cell cultures treated with thymidine, paclitaxel, or nocodazole
We asked whether cell cycle perturbations induced by compound treatment would be correctly detected by this novel multiparametric approach. U-2 OS cells were cultured in the presence of thymidine to induce cell cycle arrest at the G1/S border 20 or, alternatively, nocodazole and paclitaxel to block cells in the M phase, 21, 23 with FC analysis performed in parallel for method validation. U-2 OS cells were seeded in 96-well plates in replicate and left untreated (controls) or were alternatively treated for 20 h with 15 mM thymidine, 1.7 µM paclitaxel, or 0.17 µM (50 ng/mL) nocodazole. After BrdU pulse for 15 to 20 min, 1 replicate plate was fixed in ethanol and processed by BrdU/PI staining for FC, and the other replicate plate was fixed in formaldehyde and stained for cell cycle HCA. Figure 4A shows FC DNA content histograms (upper panels) and DNA/ BrdU scatterplots (lower panels) of untreated and compoundtreated cells. For each histogram or dot plot, at least 10,000 cells were analyzed by pooling cells from 6 replicate wells. As expected, thymidine induces G1/S block and completely abolishes BrdU incorporation, whereas the mitotic inhibitors paclitaxel and nocodazole induce a G2/M block and dramatically decrease BrdU incorporation. No sub-G1 peak was apparent in compound-treated cells, confirming that no significant degree of apoptosis was induced within the 20-h time frame.
For each sample, the percentage of cells in G1, S, and G2/M phases was quantified from the corresponding histograms, and the percentage of BrdU positive cells was calculated by gating BrdU positively stained cells in the corresponding DNA/BrdU scatterplots. The results are reported in Figure 4B .
Following treatment with thymidine, G1 phase cells increased from 32.2% to 54.5%, whereas G2/M phase cells decreased slightly to 13.2%. Quantification of S phase on the basis of DNA content (PI staining) gave a result of 32.3%, but only 0.2% of cells were actively incorporating incorporated BrdU, confirming that thymidine induced a G1/S block. Both paclitaxel and nocodazole caused dramatic increases in G2/M phase cells to about 80%, coupled to decreases in G1 phase and S phase cells, as well as in BrdU incorporating cells.
Replicates of the same samples were stained for multiparametric cell cycle analysis and scored with the ArrayScan TM high-content screening (HCS) reader. Representative images in the DAPI, BrdU, cyclin B1, and phospho-H3 fluorescence channels are shown in Figure 5 : the fluorescence patterns of untreated controls clearly appear perturbed by treatment with compounds. At the doses investigated, thymidine completely abrogates BrdU and p-H3 fluorescence signals, whereas paclitaxel and nocodazole induce a decrease of BrdU incorporation and massive increases of cyclin B1 and phospho-histone H3 positive cells, in accordance with their activity as mitotic inhibitors. DNA content distributions calculated from the DAPI fluorescence are also reported in Figure 5 : qualitatively, a clear G1 block can be observed following thymidine treatment, whereas G2/M blocks clearly appear following either paclitaxel or nocodazole treatments accordingly to flow cytometry DNA histograms (Fig. 4A) .
Perturbations in BrdU incorporation, cyclin B1 expression, and histone H3 phosphorylation in these samples are reported as 3-dimensional scatterplots in Figure 6A . After 4-color staining, each sample was analyzed by means of the ArrayScan TM system in the blue (DAPI)/green (phospho-H3)/red (cyclin B1) channels with the Cytotoxicity I Cellomics's bioapplication and subsequently in the blue (DAPI)/red (cyclin B1)/far-red (BrdU) channels with the same algorithm. To compose the final 3-dimensional plots, nuclear fluorescence intensity values related to p-H3 and BrdU obtained from 2 distinct sequential acquisitions were combined cell by cell, on the basis of the position of each single cell in the field.
Combining BrdU, cyclin B1, and phospho-H3 fluorescence, at least 5 cell populations can be identified in the 3-dimensional plots. Arbitrary thresholds were applied to the 3 axes to quantify the fraction of cells belonging to each subpopulation (Fig. 6B) . For asynchronous control cells, all values were in excellent agreement with the cell cycle phase percentages obtained from flow cytometry analysis of DNA content and BrdU incorporation (Fig. 4A) . Following thymidine treatment, 80% of the cells resulted as triple negatives (population 1), no cells were found positive for BrdU incorporation (Fig. 6B, populations 2 and 3) , and about 15% of cells were found positively stained for cyclin B1 (Fig. 6B, populations 4 and 5) . This result is compatible with a G1/S block with no active BrdU incorporation, as expected ( Fig. 4B and Tobey et al. 19 and Bostock et al. 20 ). Nocodazole and paclitaxel treatments gave very similar 3-dimensional profiles, compatible with G2/M phase blocks (see also Fig. 4) .
Concentration-response effects of thymidine, paclitaxel, and nocodazole monitored by high-content cell cycle analysis
To further explore the potential of our cell cycle HCA approach, we performed dose-response treatments for each of the drugs described above. U-2 OS cells were treated for 20 h with increasing doses of thymidine (ranging from 2.3 µM to 15 mM), paclitaxel (0.2 nM to 1.7 µM), or nocodazole (0.02 nM to 0.17 µM) and processed by 4-color staining. The cell number at each concentration point was analyzed together with the fluorescence markers. U-2 OS nuclei were automatically counted by means of the ArrayScan TM reader and the resulting cell densities (average cell number/field) are reported in Figures 7A through C. As expected, all treatments resulted in cell growth inhibition: at the maximal dose, thymidine induced 55% cell growth inhibition, whereas paclitaxel and nocodazole induced about 80% cell growth inhibition.
The effects of compound treatments on DNA content are shown in Figures 7D through F. The percentage of hyperdiploid cells for each drug concentration was calculated by setting a threshold on nuclear DAPI fluorescence of 300,000 (see also Fig. 2) . Thymidine treatment did not induce significant modulation of the G2/M fraction until 15 mM (Fig. 7D) , whereas paclitaxel and nocodazole induced dramatic effects, up to about 70% G2/M at the maximal paclitaxel dose (1.7 µM) and 80% in the presence of nocodazole concentrations greater than 0.6 µM.P Figures 7G through I shows the concentration-response curves of cells positively stained for BrdU incorporation (black boxes), cyclin B1 expression (gray boxes), and histone H3 phosphorylation (open boxes) detected by high-content analysis. Treatment with thymidine decreased BrdU incorporation at doses greater than 10 µM, whereas the cyclin B1 fluorescence signal decreases significantly only at 15 mM and beyond (Fig.  7G) . Although the very low percentage of positively stained cells in untreated control cells precludes statistical confirmation of p-H3 inhibition, 17 the dose-response curve for this marker does nevertheless clearly indicate a trend toward decreased staining (insertin Fig. 7G) .
Paclitaxel treatment inhibited BrdU incorporation and progressively increased both cyclin B1 and p-H3 positively stained cells at doses above 7 nM (Fig. 7H) . Similarly, nocodazole inhibited BrdU incorporation and induced increases of cyclin B1 and p-H3 positive cells at doses greater than 70 nM (Fig. 7I) . It is interesting to note that although we observed that cyclin B1 positive cells reached a maximum plateau at 70% to 80% following paclitaxel treatment, in agreement with previously published data, 22 p-H3 positive cells reached a maximum plateau of only circa 30%. The same can be observed for the nocodazole dose-response curve, demonstrating that mitosis blocks do not necessarily correlate with histone H3 phosphorylation. When possible, inhibitory concentration 50% (IC 50 ) values were calculated from the corresponding dose-response curves and are reported in Table 1 .
Multiparametric analysis of cell cycle progression from mitosis exit to G1-S phase
We also employed the 4-color procedure to study the kinetics of cell cycle progression after release from mitotic block. U-2 OS were treated with 0.17 µM nocodazole for 16 h to induce the M phase block, and then loosely attached mitotic cells were collected by shaking and replated in nocodazole-free medium. Cells were fixed and stained at different time points after replating, starting at 0.5 h. As before, duplicate wells were analyzed by flow cytometry (PI staining) as a reference method for DNA content distribution. Figure 8A shows DNA histograms obtained by flow cytometry (FC panels), and the percentages of G1, S, and G2/M phase cells are reported in Figure 8B . DNA histograms obtained from DAPI staining, together with representative pictures of nuclei, are shown in Figure 8A (As) clearly display a diploid (G1) and a tetraploid (G2/M) peak: an arbitrary threshold was applied to the DNA histograms (dotted line) to discriminate the 2 subpopulations. The percentage of cells above the threshold (hyperdiploid cells) is reported in Figure 8C . Whereas about 30% of asynchronously growing cells are hyperdiploid, this figure rises to 70% to 80% for cells blocked in nocodazole and begins to diminish from about 0.5 to 1 h after release from the block, confirming that cells were synchronized in the M phase. At 2 h postrelease, despite a determination of only 12% of cells in G2/M by FC analysis (Fig. 8C) , more than 40% were still estimated as hyperdiploid by HCA DNA content analysis. After examining the 2-h images, we concluded that overestimation of hyperdiploid cells was due to a technical artifact: newly divided cells often remained tightly attached to each other following cytokinesis (see pictures in Fig. 8A) , and their nuclei were acquired and identified as a single-diploid nucleus by the image analysis algorithm. This artifact could not be completely eliminated by excluding clustered nuclei on the basis of their area or shape, and thus it remains an intrinsic limitation for analysis of adherent cell cultures. However, after 3 h, the percentage of pseudo-hyperdiploid cells decreased to about 20%, probably owing to physiological separation of daughter cells due to cell motility. The fraction of pseudo-hyperdiploid cells steadily decreased during the following time points, to about 5% at 8 h after replating ( Fig. 8C) . At 16 h, 60% to 65% of cells were found to be hyperdiploid, consistent with flow cytometry analysis. Finally, the same samples were stained for BrdU incorporation, cyclin B1 expression, and histone H3 phosphorylation, and the percentages of positively stained cells were quantified. Results are shown in Figure 8D : at 0.5 h after replating, 70% to 80% of cells were found positive for both cyclin B1 and p-H3, whereas BrdU positive cells were absent; cyclin B1/p-H3 positive cells decreased slightly by 1 h (55%-60%) and completely disappeared starting from 2 h postrelease. The kinetic profile of cyclin B1 decrease after replating in nocodazole-free medium was in excellent agreement with published data. 25 The percentage of BrdU positive cells started to increase at 6 h, reaching about 20% at 8 h and 60% to 65% at 16 h, in agreement with flow cytometry analysis (Fig. 8B) .
CONCLUSIONS
In situ analysis and quantification of the cell cycle phases is problematic for adherent cell populations. Although automated microscopy, particularly HCA systems such as Cellomics's ArrayScan TM , allows multiparametric acquisition of cellular markers, current HCA approaches for cell cycle analysis of adherent cells are mainly based on the quantification of the DNA content, sometimes coupled to other cell cycle-related markers, which do not allow accurate tracking of each specific cell cycle phase. 3, 17 We have found that in some cases, estimation of DNA content by HCS technology can be affected by modifications of the nuclear morphology (fragmentation, condensation, or polynucleus formation) following compound treatments (not shown). Coupling DNA content analysis to independent cell cycle markers detected by immunofluorescence could be envisioned to improve such analytical approaches.
Here we describe a 4-color multiparametric method for cell cycle analysis by automated microscopy: the ArrayScan TM system was used to quantify DNA content by DAPI staining alongside measurement of BrdU incorporation (far-red fluorescence), cyclin B1 expression (red fluorescence), and histone H3 Ser28 phosphorylation (green fluorescence) within a single acquisition. The staining procedure avoided cross-talking among fluorescence channels, which could potentially affect results. In particular, primary and secondary antibodies were chosen to separate fluorescence signals by means of their emission spectra and their physical localization within cells. We demonstrated that this novel high-content cell cycle analysis method allows accurate quantification of cell cycle phases in asynchronous cell populations and detection of specific cell cycle blocks induced by treatment with thymidine, paclitaxel, or nocodazole, as compared with flow cytometric analysis of DNA content and BrdU incorporation. Kinetic analysis of cell cycle progression from mitosis exit to S phase was also successfully performed, with results in excellent agreement with FC analysis performed in parallel as well as with previously published data. 25 Taken together, our data demonstrate that this 4-channel HCA approach can be used for multiparametric cell cycle analysis.
